UM

Browse/Search Results:  1-7 of 7 Help

Selected(0)Clear Items/Page:    Sort:
20(S)-Protopanaxdiol Suppresses the Abnormal Granule-Monocyte Differentiation of Hematopoietic Stem Cells in 4T1 Breast Cancer-Bearing Mouse Journal article
Evidence-based Complementary and Alternative Medicine, 2020,Volume: 2020
Authors:  Guo,Wen Qin;  Chen,Ying Ge;  Shi,Rong Zhen;  He,Kai;  Wang,Jian Feng;  Shao,Jin Hui;  Wan,Jian Bo;  Gao,Jian Li
Favorite |  | TC[WOS]:1 TC[Scopus]:1 | Submit date:2021/03/02
Research and development of mAb drugs in China: a look from policy perspectives Journal article
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019,Volume: 15,Issue: 11,Page: 2695-2705
Authors:  Rong Jiang;  Yuanyuan Sun;  Carolina Ung;  Xinyue Dong;  Xiangjun Kong;  Yuanjia Hu;  Rong Shao
Favorite |  | TC[WOS]:0 TC[Scopus]:0 | Submit date:2020/03/12
r&d Support And Guidance Policy  Clinical Trial Policy  Drug Lag  Innovation Support System  Mab Drugs  Marketing Approval Policy  
China's new policy for healthcare cost-control based on global budget: a survey of 110 clinicians in hospitals Journal article
BMC Health Services Research, 2019,Volume: 19
Authors:  Jianzhou Yan;  Hui-Heng Lin;  Dan Zhao;  Yuanjia Hu;  Rong Shao
Favorite |  | TC[WOS]:4 TC[Scopus]:4 | Submit date:2020/10/23
China Healthcare Budget Crisis  Healthcare Cost-control Policy  Hospitals' Healthcare Cost-control Actions  Clinician Survey  Healthcare Performance  Patient Satisfaction  
Collaboration networks for R&D of monoclonal antibodies: An analysis based on pipeline projects Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码: 135-158
Authors:  Tianhong Yin;  Xiangjun Kong;  Yitao Wang;  Xin Chen;  Yuanjia Hu;  Rong Shao
Favorite |  | TC[WOS]:0 TC[Scopus]:0 | Submit date:2019/01/14
Monoclonal Antibodies  Research And Development  Network Analysis  Institutional Collaboration Network  Country-based Collaboration Network  
Pharmaceutical patent valuation based on empirical models Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码: 209-220
Authors:  Jingyun Ni;  Rong Shao;  Carolina Oi Lam Ung;  Yitao Wang;  Yuanjia Hu;  Yong Cai
Favorite |  | TC[WOS]:0 TC[Scopus]:0 | Submit date:2019/01/14
Pharmaceutical Patents  Patent Value  Valuation  Echnological Factors  Commercial Factors  Legal Factors  
Research and development of antibiotics: Insights from patents and citation network Journal article
Expert Opinion on Therapeutic Patents, 2016,Volume: 26,Issue: 5,Page: 617-627
Authors:  Zhang,Meng;  Kong,Xiangjun;  Zheng,Jun;  Wan,Jian Bo;  Wang,Yitao;  Hu,Yuanjia;  Shao,Rong
Favorite |  | TC[WOS]:3 TC[Scopus]:3 | Submit date:2021/03/01
Antibiotics  patent  patent citation network  technology flows  technology landscape  
Valuation of Pharmaceutical Patents: A Comprehensive Analytical Framework Based on Technological, Commercial, and Legal Factors Journal article
Journal of Pharmaceutical Innovation, 2015,Volume: 10,Issue: 3,Page: 281-285
Authors:  Ni,Jingyun;  Shao,Rong;  Ung,Carolina Oi Lam;  Wang,Yitao;  Hu,Yuanjia;  Cai,Yong
Favorite |  | TC[WOS]:1 TC[Scopus]:2 | Submit date:2021/03/01
Commercial factors  Legal factors  Patent value  Pharmaceutical patents  Technological factors  Valuation